
HEI Therapeutics provides a medical-grade home monitoring system that helps people with hypothyroidism track their condition and receive continuous care. The company combines microfluidics and microtechnology hardware with artificial intelligence-powered analytics to deliver a digital therapeutics solution for at-home testing and monitoring. Its product is developed in collaboration with patients and clinicians and is positioned for integration into clinical workflows and remote-care programs. HEI targets hypothyroidism patients and healthcare providers seeking ongoing, objective monitoring outside the clinic. The company addresses a large global market of diagnosed and undiagnosed hypothyroidism patients by enabling more frequent measurement and data-driven treatment decisions.

HEI Therapeutics provides a medical-grade home monitoring system that helps people with hypothyroidism track their condition and receive continuous care. The company combines microfluidics and microtechnology hardware with artificial intelligence-powered analytics to deliver a digital therapeutics solution for at-home testing and monitoring. Its product is developed in collaboration with patients and clinicians and is positioned for integration into clinical workflows and remote-care programs. HEI targets hypothyroidism patients and healthcare providers seeking ongoing, objective monitoring outside the clinic. The company addresses a large global market of diagnosed and undiagnosed hypothyroidism patients by enabling more frequent measurement and data-driven treatment decisions.
Product: ThyroidSense — medical-grade home-monitoring solution for hypothyroidism
Founded: 2021
Headquarters: Copenhagen, Denmark
Known investor: BioInnovation Institute (convertible note, Sep 24, 2021)
Hypothyroidism monitoring and remote management
2021
Biotechnology
Single recorded funding event listed as a convertible note
“BioInnovation Institute listed as lead investor on convertible note (Sep 24, 2021)”